Scilex Holding Company

SCLX Healthcare Drug Manufacturers General

Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024. In the quarter to June 2026, revenue fell 22.8%, EPS fell 124.4%, free cash flow fell 203.8% and total debt rose 102.7%, each against the same quarter a year earlier.

2.83 0.01 +0.35%
Market cap
$19.8M
P/E
0.0×
Fwd P/E
−7.5×
Dividend yield
—
F-score
3/9
Altman Z
−7.96
Beneish M
−7.77
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 3 2 3
ROE
192.22% 199.06% 180.29% 160.27%
ROA
(199.75%) (175.78%) (225.26%) (265.83%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
109.97% 93.23% 94.01% 96.78%
Average Days of Receivables
107.99 183.92 114.76 74.36
Free Cash Flow per Share
2.05 0.33 (0.48) (2.59)
Free Cash Flow
23.82 3.65 (3.30) (17.82)
Other line items

Show all line items

Columns are period end dates